LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 10 of 15: Cell count and normalized growth rate inhibition values within biological replicate 3. - Dataset (ID:20247)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-231 | Neratinib | 0.37 | uM | LJP5 | 1 | A16 | 72 | hr | 1235 | 3546 | 4474 | 0.7925 | 0.7644 |
MDA-MB-231 | Neratinib | 0.37 | uM | LJP5 | 2 | A16 | 72 | hr | 1235 | 3398 | 4578 | 0.7422 | 0.7080 |
MDA-MB-231 | Neratinib | 0.37 | uM | LJP5 | 3 | A16 | 72 | hr | 1235 | 3669 | 4929 | 0.7443 | 0.7250 |
MDA-MB-231 | Neratinib | 1.11 | uM | LJP5 | 1 | A15 | 72 | hr | 1235 | 2014 | 4474 | 0.4501 | 0.3009 |
MDA-MB-231 | Neratinib | 1.11 | uM | LJP5 | 2 | A15 | 72 | hr | 1235 | 2553 | 4578 | 0.5576 | 0.4681 |
MDA-MB-231 | Neratinib | 1.11 | uM | LJP5 | 3 | A15 | 72 | hr | 1235 | 2698 | 4929 | 0.5473 | 0.4787 |
MDA-MB-231 | Neratinib | 3.33 | uM | LJP5 | 1 | A14 | 72 | hr | 1235 | 1507 | 4474 | 0.3368 | 0.1127 |
MDA-MB-231 | Neratinib | 3.33 | uM | LJP5 | 2 | A14 | 72 | hr | 1235 | 1589 | 4578 | 0.3471 | 0.1422 |
MDA-MB-231 | Neratinib | 3.33 | uM | LJP5 | 3 | A14 | 72 | hr | 1235 | 1523 | 4929 | 0.3090 | 0.1103 |
MDA-MB-231 | Neratinib | 10 | uM | LJP5 | 1 | A13 | 72 | hr | 1235 | 1079 | 4474 | 0.2411 | -0.0706 |
MDA-MB-231 | Neratinib | 10 | uM | LJP5 | 2 | A13 | 72 | hr | 1235 | 801 | 4578 | 0.1750 | -0.2051 |
MDA-MB-231 | Neratinib | 10 | uM | LJP5 | 3 | A13 | 72 | hr | 1235 | 513 | 4929 | 0.1041 | -0.3564 |
BT-20 | Neratinib | 0.04 | uM | LJP5 | 1 | A18 | 72 | hr | 1097 | 2621 | 3735 | 0.7017 | 0.6367 |
BT-20 | Neratinib | 0.04 | uM | LJP5 | 2 | A18 | 72 | hr | 1097 | 2956 | 3877 | 0.7623 | 0.7231 |
BT-20 | Neratinib | 0.04 | uM | LJP5 | 3 | A18 | 72 | hr | 1097 | 3103 | 3925 | 0.7905 | 0.7600 |
BT-20 | Neratinib | 0.12 | uM | LJP5 | 1 | A17 | 72 | hr | 1097 | 2410 | 3735 | 0.6452 | 0.5608 |
BT-20 | Neratinib | 0.12 | uM | LJP5 | 2 | A17 | 72 | hr | 1097 | 2721 | 3877 | 0.7017 | 0.6465 |
BT-20 | Neratinib | 0.12 | uM | LJP5 | 3 | A17 | 72 | hr | 1097 | 2749 | 3925 | 0.7003 | 0.6478 |
BT-20 | Neratinib | 0.37 | uM | LJP5 | 1 | A16 | 72 | hr | 1097 | 2129 | 3735 | 0.5700 | 0.4551 |
BT-20 | Neratinib | 0.37 | uM | LJP5 | 2 | A16 | 72 | hr | 1097 | 2131 | 3877 | 0.5495 | 0.4397 |
BT-20 | Neratinib | 0.37 | uM | LJP5 | 3 | A16 | 72 | hr | 1097 | 2522 | 3925 | 0.6425 | 0.5723 |
BT-20 | Neratinib | 1.11 | uM | LJP5 | 1 | A15 | 72 | hr | 1097 | 1890 | 3735 | 0.5060 | 0.3603 |
BT-20 | Neratinib | 1.11 | uM | LJP5 | 2 | A15 | 72 | hr | 1097 | 2021 | 3877 | 0.5212 | 0.3984 |
BT-20 | Neratinib | 1.11 | uM | LJP5 | 3 | A15 | 72 | hr | 1097 | 2127 | 3925 | 0.5419 | 0.4332 |
BT-20 | Neratinib | 3.33 | uM | LJP5 | 1 | A14 | 72 | hr | 1097 | 1496 | 3735 | 0.4005 | 0.1917 |